Inhibiting COX-2 — an enzyme associated with inflammation — could provide a novel therapeutic approach for stress-related psychiatric disorders.

A newly identified protein interaction that affects cell cycle regulation may be an attractive target for cancer therapy.

To study the dynamics of structural proteins in the heart, Vanderbilt investigators generated a cellular tool they expect will be useful for screening drugs that affect heart muscle contraction.

Vanderbilt neurologists have identified a protein modification that could be targeted to reduce neuronal excitability in epilepsy.

A computational method that uses hospital billing codes and electronic health records can identify genetic disease cases before clinical teams do.

The National Institutes of Health (NIH) has selected Joshua Denny, MD, MS, vice president of Personalized Medicine at Vanderbilt University Medical Center, to be the chief executive officer of the federal All of Us Research Program.

The identification of a protein important for insulin synthesis may hold clues for understanding the pathogenesis of diabetes.